416 related articles for article (PubMed ID: 37852736)
1. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0.
Pavlick AC; Ariyan CE; Buchbinder EI; Davar D; Gibney GT; Hamid O; Hieken TJ; Izar B; Johnson DB; Kulkarni RP; Luke JJ; Mitchell TC; Mooradian MJ; Rubin KM; Salama AK; Shirai K; Taube JM; Tawbi HA; Tolley JK; Valdueza C; Weiss SA; Wong MK; Sullivan RJ
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37852736
[TBL] [Abstract][Full Text] [Related]
2. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer.
Kelly RJ; Bever K; Chao J; Ciombor KK; Eng C; Fakih M; Goyal L; Hubbard J; Iyer R; Kemberling HT; Krishnamurthi S; Ku G; Mordecai MM; Morris VK; Paulson AS; Peterson V; Shah MA; Le DT
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37286304
[TBL] [Abstract][Full Text] [Related]
3. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer.
Silk AW; Barker CA; Bhatia S; Bollin KB; Chandra S; Eroglu Z; Gastman BR; Kendra KL; Kluger H; Lipson EJ; Madden K; Miller DM; Nghiem P; Pavlick AC; Puzanov I; Rabinowits G; Ruiz ES; Sondak VK; Tavss EA; Tetzlaff MT; Brownell I
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35902131
[TBL] [Abstract][Full Text] [Related]
4. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
5. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma.
Govindan R; Aggarwal C; Antonia SJ; Davies M; Dubinett SM; Ferris A; Forde PM; Garon EB; Goldberg SB; Hassan R; Hellmann MD; Hirsch FR; Johnson ML; Malik S; Morgensztern D; Neal JW; Patel JD; Rimm DL; Sagorsky S; Schwartz LH; Sepesi B; Herbst RS
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35640927
[TBL] [Abstract][Full Text] [Related]
6. Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC).
Chae YK; Arya A; Iams W; Cruz MR; Chandra S; Choi J; Giles F
J Immunother Cancer; 2018 May; 6(1):39. PubMed ID: 29769148
[TBL] [Abstract][Full Text] [Related]
7. The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition.
Kreidieh FY; Tawbi HA
Ther Adv Med Oncol; 2023; 15():17588359231186027. PubMed ID: 37484526
[TBL] [Abstract][Full Text] [Related]
8. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies.
Atkins MB; Ascierto PA; Feltquate D; Gulley JL; Johnson DB; Khushalani NI; Sosman J; Yap TA; Kluger H; Sullivan RJ; Tawbi H
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36918225
[TBL] [Abstract][Full Text] [Related]
9. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer.
Disis ML; Adams SF; Bajpai J; Butler MO; Curiel T; Dodt SA; Doherty L; Emens LA; Friedman CF; Gatti-Mays M; Geller MA; Jazaeri A; John VS; Kurnit KC; Liao JB; Mahdi H; Mills A; Zsiros E; Odunsi K
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37295818
[TBL] [Abstract][Full Text] [Related]
10. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer.
Emens LA; Adams S; Cimino-Mathews A; Disis ML; Gatti-Mays ME; Ho AY; Kalinsky K; McArthur HL; Mittendorf EA; Nanda R; Page DB; Rugo HS; Rubin KM; Soliman H; Spears PA; Tolaney SM; Litton JK
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34389617
[TBL] [Abstract][Full Text] [Related]
11. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.
Komatsubara KM; Carvajal RD
Curr Oncol Rep; 2017 Jul; 19(7):45. PubMed ID: 28508938
[TBL] [Abstract][Full Text] [Related]
13. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma.
Greten TF; Abou-Alfa GK; Cheng AL; Duffy AG; El-Khoueiry AB; Finn RS; Galle PR; Goyal L; He AR; Kaseb AO; Kelley RK; Lencioni R; Lujambio A; Mabry Hrones D; Pinato DJ; Sangro B; Troisi RI; Wilson Woods A; Yau T; Zhu AX; Melero I
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34518290
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
15. An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0.
Sullivan RJ; Atkins MB; Kirkwood JM; Agarwala SS; Clark JI; Ernstoff MS; Fecher L; Gajewski TF; Gastman B; Lawson DH; Lutzky J; McDermott DF; Margolin KA; Mehnert JM; Pavlick AC; Richards JM; Rubin KM; Sharfman W; Silverstein S; Slingluff CL; Sondak VK; Tarhini AA; Thompson JA; Urba WJ; White RL; Whitman ED; Hodi FS; Kaufman HL
J Immunother Cancer; 2018 May; 6(1):44. PubMed ID: 29848375
[TBL] [Abstract][Full Text] [Related]
16. Proteomic profiling of a patient with cutaneous melanoma metastasis regression following topical contact sensitizer diphencyprone and immune checkpoint inhibitor treatment.
Han J; Agarwal A; Young JN; Owji S; Luu Y; Poplausky D; Yassky D; Estrada Y; Ungar J; Krueger JG; Gulati N
Sci Rep; 2022 Dec; 12(1):22364. PubMed ID: 36572780
[TBL] [Abstract][Full Text] [Related]
17. Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort.
Bai X; Kim M; Kasumova G; Si L; Tang B; Cui C; Yang X; Wei X; Cohen J; Lawrence D; Freedman C; Fadden R; Rubin K; Sharova T; Frederick D; Flaherty K; Sullivan R; Guo J; Boland G
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33632901
[TBL] [Abstract][Full Text] [Related]
18. Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy.
Rizvi N; Ademuyiwa FO; Cao ZA; Chen HX; Ferris RL; Goldberg SB; Hellmann MD; Mehra R; Rhee I; Park JC; Kluger H; Tawbi H; Sullivan RJ
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36918220
[TBL] [Abstract][Full Text] [Related]
19. Current Status and Molecular Mechanisms of Resistance to Immunotherapy in Oral Malignant Melanoma.
Usta SZ; Uchihashi T; Kodama S; Kurioka K; Inubushi T; Shimooka T; Sugauchi A; Seki S; Tanaka S
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139110
[TBL] [Abstract][Full Text] [Related]
20. Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study).
Nakamura Y; Namikawa K; Yoshikawa S; Kiniwa Y; Maekawa T; Yamasaki O; Isei T; Matsushita S; Nomura M; Nakai Y; Fukushima S; Saito S; Takenouchi T; Tanaka R; Kato H; Otsuka A; Matsuya T; Baba N; Nagase K; Inozume T; Fujimoto N; Kuwatsuka Y; Onishi M; Kaneko T; Onuma T; Umeda Y; Ogata D; Takahashi A; Otsuka M; Teramoto Y; Yamazaki N
ESMO Open; 2021 Dec; 6(6):100325. PubMed ID: 34839104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
